Methotrexate therapy in dermatology;Therapie mit Methotrexat in der Dermatologie

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 5, 2012, Pages 363-370

  Reich, Kristian ^a   Domm, Silja ^b   Mrowietz, Ulrich ^b  

^a Dermatologikum Hamburg   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTICLE; DERMATOLOGY; HUMAN;

EID: 84860479106     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.07926.x     Document Type: Article

References (69)

1. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B,. [S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges 2011; 9 Suppl 2: S1-104.
2. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne J P, Orze-chowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 Suppl 2: 1-70.
3. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K,. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72. (Pubitemid 351630108)
4. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH,. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotr-exate in psoriasis. J Invest Dermatol 2007; 127: 1860-7. (Pubitemid 47075365)
5. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt W F, Bossuyt PM, Bos JD, de Rie MA,. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65. (Pubitemid 36975998)
6. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne J P, Unnebrink K, Kaul M, Camez A,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66. (Pubitemid 351239154)
7. Dicken CH,. Treatment of classic pityriasis rubra pilaris. J Am Acad Derma-tol 1994; 31: 997-9. (Pubitemid 24365041)
8. Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH,. Pityriasis rubra pilaris in children. J Am Acad Dermatol 2002; 47: 386-9.
9. Said BB, Kanitakis J, Graber I, Nicolas J F, Saurin JC, Berard F,. Pityriasis lichenoides chronica induced by adalimu-mab therapy for Crohn's disease: report of 2 cases successfully treated with me-thotrexate. Inflamm Bowel Dis 2010; 16: 912-3.
10. Lopez-Ferrer A, Puig L, Moreno G, Camps-Fresneda A, Palou J, Alomar A,. Pityriasis lichenoides chronica induced by infliximab, with response to methotr-exate. Eur J Dermatol 2010; 20: 511-2.
11. Lazaridou E, Fotiadou C, Tsorova C, Trachana M, Trigoni A, Patsatsi A, Ioannides D,. Resistant pityriasis lichenoides et varioliformis acuta in a 3-year-old boy: successful treatment with methotrexate. Int J Dermatol 2010; 49: 215-7.
12. Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H,. Low-dose methotr-exate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 2010; 24: 43-9.
13. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ,. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007; 156: 346-51. (Pubitemid 46095964)
14. Adisen E, Tekin O, Gulekon A, Gurer MA,. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Derma-tol Venereol 2009; 23: 814-9.
15. Yazawa N, Kondo S, Kagaya M, Yazawa H, Minamitsuji Y, Jimbow K,. Successful treatment of a patient with lymphomatoid papulosis by methotrexate. J Dermatol 2001; 28: 373-8. (Pubitemid 32738205)
16. Bories N, Thomas L, Phan A, Balme B, Salameire D, Thurot-Guillou C, Dalle S,. [Lymphomatoid papulosis in childhood: six case reports and a literature review]. Ann Dermatol Venereol 2008; 135: 657-62.
17. Kadin ME,. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park) 2009; 23: 1158-64.
18. Vonderheid EC, Sajjadian A, Kadin ME,. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lym-phoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-81. (Pubitemid 26083827)
19. Kowal-Bielecka O, Distler O,. Use of methotrexate in patients with sclero-derma and mixed connective tissue disease. Clin Exp Rheumatol 2010; 28: S160-3.
20. Beltramelli M, Vercellesi P, Frasin A, Gelmetti C, Corona F,. Localized severe scleroderma: a retrospective study of 26 pediatric patients. Pediatr Dermatol 2010; 27: 476-80.
21. Kuhn A, Ruland V, Bonsmann G,. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 2011; 65: e195-213.
22. Gurcan HM, Ahmed AR,. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161: 723-31.
23. Fendler C, Braun J,. Use of methotrexate in inflammatory myopathies. Clin Exp Rheumatol 2010; 28: S164- 7.
24. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel R P,. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009; 60: 1825-30.
25. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, Scuccimarri R, Feldman BM,. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 2010; 37: 1953- 61.
26. Lee JY,. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J 2009; 15: 8.
27. Nyfors A,. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 1978; 25: 208-11. (Pubitemid 9036688)
28. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ,. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
29. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS,. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
30. Duchet-Niedziolka P, Launay O, Coutsinos Z, Ajana F, Arlet P, Barrou B, Beytout J, Bouchaud O, Brouqui P, Buzyn A, Chidiac C, Couderc LJ, Debord T, Dellamonica P, Dhote R, Duboust A, Durrbach A, Fain O, Fior R, Godeau B, Goujard C, Hachulla E, Marchou B, Mariette X, May T, Meyer O, Milpied N, Morlat P, Pouchot J, Tattevin P, Viard J P, Lortholary O, Hanslik T,. Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine 2009; 27: 1523-9.
31. Kavanaugh A,. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheumatol 2009; 21: 419-24.
32. Izzedine H, Launay-Vacher V, Karie S, Caramella C, de Person F, Deray G,. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005; 64: 315-9. (Pubitemid 41448436)
33. Kalb RE, Strober B, Weinstein G, Lebwohl M,. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
34. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ,. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol 2002; 99: 599-602. (Pubitemid 34246297)
35. Buckley LM, Bullaboy CA, Leichtman L, Marquez M,. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971-3. (Pubitemid 27200016)
36. Temprano KK, Bandlamudi R, Moore TL,. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35: 112-21. (Pubitemid 41356587)
37. Ostensen M, Hartmann H, Salvesen K,. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000; 27: 1872-5. (Pubitemid 30670480)
38. Martinez Lopez JA, Loza E, Carmona L,. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009; 27: 678- 84.
39. Grunewald S, Paasch U, Glander HJ,. Systemic dermatological treatment with relevance for male fertility. J Dtsch Dermatol Ges 2007; 5: 15-21. (Pubitemid 46086066)
40. Griggs LR, Schwartz DA,. Successful paternity of a healthy child while taking methotrexate for Crohn's disease. Am J Gastroenterol 2006; 101: 2893-4. (Pubitemid 44902676)
41. Pieringer H, Stuby U, Biesenbach G,. The place of methotrexate perioperati-vely in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 1217-20.
42. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martin-Mola EM, Mielants H, Muller-Ladner U, Murphy G, Ostergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zoch-ling J, Dougados M,. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature re-search and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-93.
43. Miceli-Richard C, Gestermann N, Amiel C, Sellam J, Ittah M, Pavy S, Urrutia A, Girauld I, Carcelain G, Venet A, Mariette X,. Effect of methotr-exate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther 2009; 11: R77.
44. Tilling L, Townsend S, David J,. Me-thotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006; 26: 55-62. (Pubitemid 43275699)
45. Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, D'Agostino M, Gabrieli ML, Vero V, Biolato M, Pompili M, Gasbarrini G, Rapaccini G, Amerio P, De Simone C, Grieco A,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
46. Berends MA, Snoek J, de Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH, Drenth J P,. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006; 24: 805- 11.
47. Aithal G P, Haugk B, Das S, Card T, Burt AD, Record CO,. Monitoring me-thotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19: 391-9. (Pubitemid 38297107)
48. Zachariae H, Sogaard H, Heickendorff L,. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies-a further 10-year follow-up. Dermatology 1996; 192: 343-6.
49. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, Hultcrantz R,. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotr-exate treatment. J Hepatol 2007; 46: 1111-8. (Pubitemid 46669734)
50. Chalmers RJ, Kirby B, Smith A, Burrows P, Little R, Horan M, Hextall JM, Smith CH, Klaber M, Rogers S,. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005; 152: 444-50. (Pubitemid 40547117)
51. Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, Shomaf M, Haboubi NY,. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-trea-ted psoriatic patients. Br J Dermatol 1996; 135: 538-44. (Pubitemid 26341933)
52. Mitchell D, Smith A, Rowan B, Warnes TW, Haboubi NY, Lucas SB, Chalmers RJ,. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122: 1-7. (Pubitemid 20047028)
53. Maurice PD, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ,. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005; 152: 451-8. (Pubitemid 40547118)
54. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A,. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009; 48: 569-72.
55. Dervieux T, Zablocki R, Kremer J,. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 2337-45.
56. Chladek J, Simkova M, Vaneckova J, Hroch M, Chladkova J, Martinkova J, Vavrova J, Beranek M,. The effect of folic acid supplementation on the pharmacokinetics and pharmacodyna-mics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347- 55.
57. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM,. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62: 1013- 30.
58. Prey S, Paul C,. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160: 622-8.
59. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G,. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 1165-9. (Pubitemid 44729990)
60. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.
61. Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, Mooney J, Somerville M, Bosworth A, Kennedy T,. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Derma-tologists. Rheumatology (Oxford) 2008; 47: 924-5.
62. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS,. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-41.
63. Said S, Jeffes EW, Weinstein GD,. Methotrexate. Clin Dermatol 1997; 15: 781-97. (Pubitemid 27411309)
64. van de Kerkhof PC,. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001; 26: 356-61.
65. Morgan SL, Baggott JE,. Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: S102-9.
66. Daly M, Alikhan A, Armstrong AW,. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat 2011; 22: 276-84.
67. Zisman DA, McCune WJ, Tino G, Lynch J P, 3rd,. Drug-induced pneumo-nitis: the role of methotrexate. Sarcoi-dosis Vasc Diffuse Lung Dis 2001; 18: 243-52.
68. Albrecht K, Muller-Ladner U,. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: S95- 101.
69. Searles G, McKendry RJ,. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheu-matol 1987; 14: 1164-71. (Pubitemid 18049936)